Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that has generated questions about potential effects on sexual function
"Having a biosimilar, which is made by an entirely new pharmaceutical company and maybe made in a more cost-effective way would also relieve some pressures on any future shortages that we might expect," Bajaj said
If you are not completely satisfied, we will make it right
Keep snacks like crackers close by for quick relief
While retatrutide has shown greater weight loss in clinical trials (24.2% vs approximately 1517% for Wegovy), it is important to note that retatrutide targets three hormone receptors, whereas semaglutide targets only one (GLP-1)
Medicare and insurers don't cover GLP-1 patches for weight loss
